Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake

Molecular Carcinogenesis

Volumn 26, Issue 4, 1999, Pages 213-225

  Jiang, Cheng ^a   Jiang, Weiqin ^a   Ip, Clement ^b   Ganther, Howard ^c   Lu, Junxuan ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

1 methyl 1 nitrosourea; Apoptosis; Intratumoral microvessel density; Matrix metalloproteinase; Vascular epithelial growth factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; GELATINASE A; MATRIX METALLOPROTEINASE; METHYLNITROSOUREA; SELENIUM; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICARCINOGENIC AGENTS; DIET; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; GARLIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOKINES; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHYTOTHERAPY; PLANTS, MEDICINAL; RATS; RATS, SPRAGUE-DAWLEY; SELENIUM; SODIUM SELENITE; STROMAL CELLS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ALLIUM SATIVUM; ANIMALIA;

EID: 0032760588     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z     Document Type: Article

References (65)

1. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-1963.
2. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-1854.
3. Combs GF Jr, Gray WP. Chemopreventiveagents: Selenium. Pharmacol Ther 1998;79:179-192.
4. Ip C, Ganther HE. Activity of methylated forms of selenium in cancer prevention. Cancer Res 1990;50:1206-1211.
5. Ip C, Hayes C, Budnick RM, Ganther HE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991;51:595-600.
6. Lu J, Jiang C, Kaeck M, Ganther H, Vadhanavikit S, Ip C, Thompson H. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50: 213-219.
7. Lu J, Pei H, Ip C, Lisk D, Ganther H, Thompson HJ. Effect of an aqueous extract of selenium enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis 1996;17:1903-1907.
8. Kaeck M, Lu J, Strange R, Ip C, Ganther HE, Thompson HJ. Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 1997;53: 921-926.
9. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
10. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534-2539.
11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
12. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174.
13. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-424.
14. Cai XJ, Block E, Unden PC, Zhang X, Quimby BD, Sullivan JJ. Allium chemistry: Identification of selenoamino acids in ordinary and selenium-enriched garlic, onion and broccoli using gas chromatography with atomic emission detection. J Agric Food Chem 1995;43:1754-1757.
15. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
17. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5: 1806-1814.
18. Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995;1246:1-9.
19. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
20. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
21. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-13340.
22. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res 1998;58:4008-4014.
23. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basis fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015-4023.
24. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-28228.
25. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997;57: 5590-5597.
26. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55: 4575-4580.
27. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919.
28. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-3440.
29. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997;94:861-866.
30. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-277.
31. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
32. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
33. Deryugina El, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998;58:3743-3750.
34. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95:365-377.
35. Ip C, Lisk DJ. Enrichment of selenium in allium vegetables for cancer prevention. Carcinogenesis 1994;15:1881-1885.
36. Ip C, Lisk DJ. Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the action of selenium. Carcinogenesis 1995;16:2649-2652.
37. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1 nitrosourea. Cancer Res 1991;51:3411-3415.
38. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995;16:2407-2411.
39. Tonnesen MG, Jenkins D Jr, Siegal SL, Lee LA, Huff JC, Clark RA. Expression of fibronectin, laminin, and factor VIII-related antigen during development of the human cutaneous microvasculature. J Invest Dermatol 1985;85: 564-568.
40. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
41. Thaloor D, Singh AK, Sidhu GS, Prasad PV, Kleinman HK, Maheshwari RK. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell growth Differ 1998;9:305-312.
42. Nakamura J, Savinov A, Lu Q, Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 1996;137:5589-5596.
43. Zhang HT, Craft P, Scott PA, et al. Enhancement of tumor growth and vascular density for transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87: 213-219.
44. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 1998;153:1993-2006.
45. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing anti-body: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
46. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
47. Meeson AP, Argilla M, Ko K, Witte L, Lang RA. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 1999;126: 1407-1415.
48. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
49. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
50. Forsythe JA, Jiang BH, lyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-indudble factor 1. Mol Cell Biol 1996;16:4604-4613.
51. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993;90:4304-4308.
52. Damert A, Ikeda E, Risau W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 1997;327(Pt 2):419-423.
53. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J, AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997;94:3633-3638.
54. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253-32259.
55. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
56. Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci USA 1996;93:1006-1011.
57. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 1996;93: 6146-6151.
58. Gallegos A, Berggren M, Gasdaska JR, Powis G. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res. 1997;57:4965-4970.
59. Berggren M, Gallegos A, Gasdaska J, Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res 1997;17:3377-3380.
60. Christensen MJ, Pusey NW. Binding of nuclear proteins to transcription regulatory elements in selenium deficiency. Biochim Biophys Acta 1994;1225:338-341.
61. Spyrou G, Bjornstedt M, Kumar S, Holmgren A. AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett 1995;368:59-63.
62. Kim IY, Stadtman TC. Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proc Natl Acad Sci USA 1997;94:12904-12907.
63. Ganther, HE. Selenium metabolism, selenoproteins, and mechanisms of cancer prevention: Complexities with thioredoxin reductase. Carcinogenesis, in press.
64. Tyagi SC, Kumar S, Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem 1996;61: 139-151.
65. Mattana J, Margiloff L, Sharma P, Singhal PC. Oxidation of the mesangial matrix metalloproteinase-2 impairs gelatinolytic activity. Inflammation 1998;22:269-276.